Neutrophil extracellular traps (NETs) reduce the diffusion of doxorubicin which may attenuate its ability to induce apoptosis of ovarian cancer cells.
Chemosensitivity
Doxorubicin
Neutrophil extracellular traps
Pharmacokinetics
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
02
02
2022
revised:
08
04
2022
accepted:
10
06
2022
entrez:
27
6
2022
pubmed:
28
6
2022
medline:
28
6
2022
Statut:
epublish
Résumé
Although neutrophil extracellular traps (NETs) are present in various tumors, their roles in tumor biology have not been clarified yet. In this study, we examined how NETs affect the pharmacokinetics and effects of doxorubicin (DOX). NETs were generated by neutrophils stimulated with phorbol 12-myristate 13-acetate (PMA) or lipopolysaccharide (LPS). DOX was added to NETs and their distribution was observed under fluorescein microscopy, and the diffusion of DOX through 3 μM pores from lower to upper chambers was evaluated with a fluorescence-based assay. Ovarian cancer cells, KOC-2S and SKOV3, were embedded in collagen gel droplets and cultured in 3D way and their apoptosis was examined with flow cytometry. DOX was mostly co-localized with NETs. The transfer of DOX to upper chambers increased over time, which was significantly decreased by the presence of neutrophils stimulated with PMA or LPS in the lower chamber. DOX outside of the gel increased the rates of annexin V (+) apoptotic cells, which were significantly reduced by the addition of LPS-stimulated neutrophils in media both in KOC-2S and SKOV3. The reduced diffusion and apoptosis were mostly restored by the destruction of the NETs structure with 1000 u/ml DNAse I. NETs efficiently trap and inhibit the diffusion of DOX which may attenuate its ability to induce apoptosis of ovarian cancer cells. Degradation of NETs with DNAse I may augment the response of ovarian cancer to DOX.
Identifiants
pubmed: 35756123
doi: 10.1016/j.heliyon.2022.e09730
pii: S2405-8440(22)01018-0
pmc: PMC9218137
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e09730Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Science. 2018 Sep 28;361(6409):
pubmed: 30262472
J Cancer Res Clin Oncol. 2018 Mar;144(3):469-482
pubmed: 29305710
Cancer Chemother Pharmacol. 1990;25(6):435-9
pubmed: 2311172
Cancer Res. 2016 Mar 15;76(6):1367-80
pubmed: 26759232
Trends Immunol. 2016 Jan;37(1):41-52
pubmed: 26700397
J Clin Oncol. 2012 Jul 10;30(20):2449-56
pubmed: 22614976
Front Immunol. 2013 Mar 06;4:48
pubmed: 23508552
Cancers (Basel). 2022 Mar 07;14(5):
pubmed: 35267667
Nat Med. 2017 Mar 7;23(3):279-287
pubmed: 28267716
J Clin Invest. 2012 Jul;122(7):2661-71
pubmed: 22684106
Nat Med. 2014 May;20(5):511-7
pubmed: 24784231
J Eur Acad Dermatol Venereol. 2004 Jul;18(4):422-5
pubmed: 15196154
PLoS One. 2016 May 02;11(5):e0154484
pubmed: 27136460
Proc Natl Acad Sci U S A. 2010 Sep 7;107(36):15880-5
pubmed: 20798043
Cell Mol Life Sci. 2014 Nov;71(21):4179-94
pubmed: 25070012
Ann Oncol. 1994;5 Suppl 6:S3-6
pubmed: 7865431
Cancer Immunol Immunother. 2016 Nov;65(11):1317-1323
pubmed: 27565980
Cancer Res. 2011 Apr 1;71(7):2411-6
pubmed: 21427354
Nat Rev Immunol. 2013 Mar;13(3):159-75
pubmed: 23435331
Gastric Cancer. 2020 Jul;23(4):677-688
pubmed: 32036492
J Photochem Photobiol B. 2016 May;158:274-9
pubmed: 26971631
Biochimie. 1984 May;66(5):333-52
pubmed: 6380596
Jpn J Cancer Res. 2001 Feb;92(2):203-10
pubmed: 11223550
Crit Care. 2018 Jul 13;22(1):176
pubmed: 30005596
J Mol Med (Berl). 2015 Jul;93(7):727-34
pubmed: 26002146
Cancers (Basel). 2020 Jun 11;12(6):
pubmed: 32545405
Nat Rev Immunol. 2018 Feb;18(2):134-147
pubmed: 28990587
Science. 2004 Mar 5;303(5663):1532-5
pubmed: 15001782
Gynecol Oncol. 1993 Feb;48(2):155-64
pubmed: 8428685
Proc Natl Acad Sci U S A. 2012 Aug 7;109(32):13076-81
pubmed: 22826226
J Clin Invest. 2013 Jul 1;:
pubmed: 23863628
Onco Targets Ther. 2020 Oct 14;13:10417-10429
pubmed: 33116621
Cancer Med. 2019 Jul;8(8):3918-3927
pubmed: 31124302
BMC Cancer. 2017 Feb 15;17(1):135
pubmed: 28202050